

Clinical Trial Protocol

Iranian Registry of Clinical Trials

02 Jul 2026

Investigation of the Immunogenicity and Safety of Lactococcus Lactis Vaccine Containing Codon-Optimized Full-Length E7 and E6 Oncoproteins of HPV-16 in Healthy Women

Protocol summary

Study aim

The Main Objective of This Study Was to Evaluate the Immunogenicity and Safety of Oral Vaccines Containing E7 and E6 Oncoproteins of Human Papillomavirus type 16, In Order to Eventually Use These Vaccines to Treat Cervical Cancer Caused by Human Papillomavirus type 16.

Design

One Hundred Sixty Healthy Iranian Non-Pregnant Volunteer Women Aged 18 to 59 Years Were Vaccinated at the Keyvan Virology Specialty Laboratory (KVSL). Upon Enrollment, Written Consent Was Obtained From Each Participant or Her Legal Guardian.

Settings and conduct

Keyvan Virology Specialty Laboratory

Participants/Inclusion and exclusion criteria

1- People Voluntarily Participate in the Research. 2- The Informed Consent Form Is Completed and Signed by the Person or Her companion. 3- Women PCR positive test for Papilloma Virus Infection. 4. Women Don't Have other sexually transmitted diseases. Women Don't be Pregnant 6. Women in Pap smear Test Don't Have Abnormal Conditions. 7. People Don't Have Other Cancerous Disease During the Course of Treatment. 8. Failure to Complete a Course of Treatment by Individuals Will Result in Their Exclusion from Study. 9- Getting Pregnant During the Course of Treatment Will Leave Women Out of Study.

Intervention groups

In This Study, There Are Six Target Groups That All Groups Are Identical in Terms of Health Standards, But Differ in Terms of Drug Use. This Will be Given to Three Groups (Test Groups) of the E7 and E6 Vaccine and Will be Given to the Following Three (Control Groups) Groups of Placebo.

Main outcome variables

Immunogenicity and Safety of Vaccines

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20190504043464N1**

Registration date: **2019-05-19, 1398/02/29**

Registration timing: **retrospective**

Last update: **2019-05-19, 1398/02/29**

Update count: **0**

Registration date

2019-05-19, 1398/02/29

Registrant information

Name

Sedigheh Taghinezhad Saroukalaei

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 21 8854 9747

Email address

s.taghinezhad@srbiau.ac.ir

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2018-12-22, 1397/10/01

Expected recruitment end date

2019-02-09, 1397/11/20

Actual recruitment start date

2018-12-22, 1397/10/01

Actual recruitment end date

2019-02-19, 1397/11/30

Trial completion date

2019-02-20, 1397/12/01

Scientific title

Investigation of the Immunogenicity and Safety of Lactococcus Lactis Vaccine Containing Codon-Optimized Full-Length E7 and E6 Oncoproteins of HPV-16 in Healthy Women

Public title

Investigating of the Immunogenicity and Safety of Lactococcus Lactis Vaccine Related to Human Papillomavirus Type 16

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion criteria:

1- People Voluntarily Participate in the Research. 2- The Informed Consent Form Is Completed and Signed by the Person or Her companion. 3- Women PCR positive test for Papilloma Virus Infection. 4. Women Don't Have other sexually transmitted diseases. Women Don't be Pregnant 6. Women in Pap smear Test Don't Have Abnormal Conditions.

Exclusion criteria:

1. People Don't Have Cancerous Disease During the Course of Treatment. 2. Failure to Complete a Course of Treatment by Individuals Will Result in Their Exclusion from Study. 3- Getting Pregnant During the Course of Treatment Will Leave Women Out of Study.

Age

From **18 years** old to **59 years** old

Gender

Female

Phase

1

Groups that have been masked

- Participant

Sample size

Target sample size: **200**

Actual sample size reached: **160**

Randomization (investigator's opinion)

Randomized

Randomization description

Volunteers Who Met eligibility Criteria Were Randomized Into Six Clinical Groups in a 2:1 Correlation Using Randomizer Software (Version 3.0) To Receive Four Rounds of Oral Vaccination using the E7 or E6 Vaccine or a Placebo at Weeks 1, 2, 4, and 8. Each Dose of Vaccine was Administered Orally, Once Each Morning After Fasting For Five Days, Each Treatment Week.

Blinding (investigator's opinion)

Single blinded

Blinding description

In This Study, Healthy Women Are Divided Into Six Groups. In This Phase, All Groups Are Treated and Simultaneously Given to Three Groups of Vaccines and Given to the Other Three Groups of Placebo.

Placebo

Used

Assignment

Parallel

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Iran University of Medical Sciences

Street address

Iran University of Medical Sciences, Shahid Hemmat Highway, Tehran

City

Tehran

Province

Tehran

Postal code

۱۴۳۹۶۱۴۵۳۵

Approval date

2016-12-20, 1395/09/30

Ethics committee reference number

1395.95-04-30-29914

Health conditions studied

1

Description of health condition studied

Genital Wart

ICD-10 code

A63.0

ICD-10 code description

Anogenital (venereal) warts

Primary outcomes

1

Description

Change in Antibody and Interferon Levels

Timepoint

At the Beginning of the Study, 30, 60 and 90 Days After Taking the Vaccine.

Method of measurement

ELISA And ELISPOT KITS

Secondary outcomes

empty

Intervention groups

1

Description

Intervention group: Volunteers Receive Four Rounds of Oral Vaccine (1 mL) at Weeks 1, 2, 4, and 8. Each Dose of Vaccine Was Administered Orally, Once Each Morning After Fasting For Five Days, Each Treatment Week. If No Side Effects Were Detected in Arms Given the Lower

Dose (10000000000 CFU/mL), the Dose Was Escalated to 50000000000 CFU/mL and 100000000000 CFU/mL.

Category

Treatment - Other

2**Description**

Control group: Control Groups Receive Four Rounds of Placebo (1 mL) at Weeks 1, 2, 4, and 8. Each Dose of Placebo Was Administered Orally, Once Each Morning After Fasting For Five Days, Each Treatment Week. If No Side Effects Were Detected in Arms Given the Lower Dose (10000000000 CFU/mL), the Dose Was Escalated to 50000000000 CFU/mL and 100000000000 CFU/mL.

Category

Treatment - Other

Recruitment centers**1****Recruitment center****Name of recruitment center**

Keyvan Virology Specialty Laboratory

Full name of responsible person

Hossein Keyvani

Street address

Floor 1, Number 498, Beheshti Avenue

City

Tehran

Province

Tehran

Postal code

1596983911

Phone

+98 21 8870 6556

Fax

+98 21 8870 6555

Email

keyvani.h@iums.ac.ir

Sponsors / Funding sources**1****Sponsor****Name of organization / entity**

Iran University of Medical Sciences

Full name of responsible person

Dr. Seyed Kazem Malakoti

Street address

Tehran, Hemmat Highway, next to Milad Tower, Iran University of Medical Sciences

City

Tehran

Province

Tehran

Postal code

1449614535

Phone

+98 21 86709

Email

s.taghinezhad@srbiau.ac.ir

Grant name**Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

Title of funding source

Iran University of Medical Sciences

Proportion provided by this source

50

Public or private sector

Private

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin**Type of organization providing the funding**

Academic

Person responsible for general inquiries**Contact****Name of organization / entity**

Islamic Azad University

Full name of responsible person

Amir Hossein Mohseni

Position

Researcher

Latest degree

Ph.D.

Other areas of specialty/work

Microbiology

Street address

Floor 1, Number 498, Shahid Beheshti ave, Tehran.

City

Tehran

Province

Tehran

Postal code

1596983911

Phone

+98 21 8871 6556

Fax

+98 21 8871 6555

Email

amho.mohseni@gmail.com

Person responsible for scientific inquiries**Contact****Name of organization / entity**

Islamic Azad University

Full name of responsible person

Sedigheh Taghinezhad Saroukalaei

Position

Researcher

Latest degree

Ph.D.

Other areas of specialty/work

Microbiology

Street address

Floor 1, No. 498, Shahid Beheshti Ave., Tehran.

City

Tehran

Province

Tehran

Postal code

1596983911

Phone

+98 21 8871 6556

Fax

+98 21 8871 6555

Email

taghinezhad.m@gmail.com

Person responsible for updating data

Contact

Name of organization / entity

Islamic Azad University

Full name of responsible person

Amir Hossein Mohseni

Position

Researcher

Latest degree

Ph.D.

Other areas of specialty/work

Microbiology

Street address

Floor 1, No. 498, Shahid Beheshti Ave., Tehran.

City

Tehran

Province

Tehran

Postal code

1596983911

Phone

+98 21 8871 6556

Fax

+98 21 8871 6555

Email

amho.mohseni@gmail.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)

Undecided - It is not yet known if there will be a plan to make this available

Study Protocol

Undecided - It is not yet known if there will be a plan to make this available

Statistical Analysis Plan

Undecided - It is not yet known if there will be a plan to make this available

Informed Consent Form

Undecided - It is not yet known if there will be a plan to make this available

Clinical Study Report

Undecided - It is not yet known if there will be a plan to make this available

Analytic Code

Undecided - It is not yet known if there will be a plan to make this available

Data Dictionary

Undecided - It is not yet known if there will be a plan to make this available